Background {#Sec1}
==========

Indigenous Peoples residing in northern Canada have an elevated prevalence of *Helicobacter pylori* (*Hp*) infection relative to southern Canadians \[[@CR1]\]. This bacterial infection can persist lifelong, causing chronic inflammation of the stomach lining; in a small proportion of cases (5--15%), it causes peptic ulcer disease and, more rarely, stomach cancer \[[@CR2]\]. Elevated *Hp* prevalence and stomach cancer rates have been observed in Indigenous communities across the circumpolar north relative to the average occurrence in the respective countries \[[@CR1]\].

Systematic reviews of population-based studies report *Hp* prevalence estimates over 50% across most of Africa, Asia and Latin America, with lower and declining prevalence in Australia-New Zealand, Europe and North America \[[@CR3], [@CR4]\]. While *Hp* prevalence varies substantially within countries by ethnicity and socioeconomic status, and many region-specific prevalence estimates come from unrepresentative samples \[[@CR5]\], rough regional estimates range from 24% for Australia-New Zealand to 79% for Africa, with prevalence in Canada and the United States estimated at 36 and 38%, respectively, in a 2017 systematic review \[[@CR3]\]. Evidence from the late twentieth century showed *Hp* prevalence inversely associated with socioeconomic status within Europe and the United States \[[@CR6], [@CR7]\]. Because the infection typically is acquired in childhood, observed increases in *Hp* prevalence with age result from a cohort effect reflecting transmission levels within the first years after birth. Decreases in *Hp* prevalence observed in younger age groups in affluent countries suggests that transmission is decreasing in such countries, though it remains high in socioeconomically disadvantaged groups. In Canada, for example, the prevalence in pediatric patients residing in major urban centers was estimated in 2005 at just 5%, while 56% (92/163) of Wasagamack Cree children in northern Manitoba screened positive for *Hp* in 2002 \[[@CR2], [@CR8]\].

The Canadian North *Helicobacter pylori* (CAN*Help*) Working Group, a collaboration of academic scientists with Indigenous community leaders and their health care providers \[[@CR9]\], conducts community-driven investigations focused on *Hp* infection in the Northwest Territories (NT) and Yukon (YT) \[[@CR10]--[@CR16]\]. Incorporating the perspective of those who bear the burden, results from these projects will be used to develop *Hp* control strategies that are cost-effective and culturally appropriate for Arctic Indigenous communities. Previous reports describe details of CAN*Help* projects and their community-driven approaches \[[@CR10], [@CR12]--[@CR15], [@CR17]\]. This paper describes the burden of disease from *Hp* infection among participants in CAN*Help* community projects.

Methods {#Sec2}
=======

Research sought by communities {#Sec3}
------------------------------

The CAN*Help* research program arose from the confluence of three constituencies: residents of western Canadian Arctic communities worried about *Hp* infection and its link to stomach cancer; health care practitioners frustrated by poor effectiveness of available clinical management strategies for this frequently encountered infection; and public health officials seeking evidence to inform infection control strategies. In the early 2000s, NT health care officials sought input from University of Alberta researchers to respond to concerns voiced by community leaders. In 2006, a meeting between academic scientists and NT medical directors generated support for community-driven research aimed at describing the burden of disease from *Hp* infection in concerned communities. NT health care partners recommended the Hamlet of Aklavik for the initial project because Aklavik community leaders had advocated for research to reduce health risks from *Hp* infection. The Aklavik *H. pylori* Project launched in 2007. Word of its success generated interest in neighboring communities. Invited by community leaders, the research team launched community *H. pylori* Projects in Old Crow YT in 2010, Tuktoyaktuk NT in 2011 and Fort McPherson NT in 2012. Projects launched in 2016--2017 are not included in this report. The University of Alberta Health Research Ethics Board approved this research, and as required by law, we obtained annual research licenses in both NT and YT before collecting data.

Participating communities {#Sec4}
-------------------------

Population estimates (from census nearest project launch) were 594 (2006) for Aklavik, 245 (2011) for Old Crow, 854 (2011) for Tuktoyaktuk, and 792 (2011) for Fort McPherson (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR18]--[@CR21]\]. Most residents of participating communities identify as Indigenous: by census counts, in Aklavik, 92% were Indigenous (mainly Inuvialuit (western Canadian Inuit) or Gwich'in (Athabaskan) First Nation); in Old Crow, 90% were Vuntut Gwitchin (Athabaskan) First Nation; in Tuktoyaktuk, 92% were Inuvialuit; and in Fort McPherson, 94% were Indigenous (mainly Gwich'in) \[[@CR18], [@CR22]\]. Aklavik, 113 km south of the Arctic Coast, is accessible by air, ice road in winter and water in summer \[[@CR23]\]. Old Crow, north of the Arctic Circle on the Porcupine River, is accessible only by air \[[@CR24]\]. Tuktoyaktuk, on the Arctic Ocean coast, is accessible by air, highway year-round since November 2017 (before that by ice road in winter). Fort McPherson, on the Peel River, is accessible by highway year-round \[[@CR23]\].Fig. 1Map of the western Canadian Arctic with partner community locations indicated. Inset shows logos of community projects that had contests to select a logo created by a local artist: Fort McPherson *H. pylori* Project (local artist -- Johanna Edwards); Old Crow *H. pylori* Project (local artist -- Mary Jane Moses); Aklavik *H. pylori* Project (local artist -- Richard Papik). Map adapted from <https://commons.wikimedia.org/wiki/File:Map_Canada_political-geo.png>

Community-driven approach {#Sec5}
-------------------------

Each project launch required the formation of a planning committee of community residents; the process for recruiting committee members was devised by community partners. An exception was the Tuktoyaktuk project, launched at the request of the Inuvialuit Regional Corporation \[[@CR25]\], with planning occurring in partnership with regional Inuvialuit leadership and a Tuktoyaktuk community health representative. Planning committees and other community partners provided input on design and implementation of all research activities to ensure they adhered to community priorities and cultural values. Planning committees and other community partners reviewed all research reports before they were made public.

Study population and design {#Sec6}
---------------------------

Project recruitment activities in each community encouraged all residents to participate in baseline research activities: interviewer-administered questionnaires; *Hp* screening; and endoscopy with gastric biopsies for culture and pathological examination. After endoscopy activities concluded, randomized trials offered treatment to eliminate *Hp* infection to those testing positive. Participants gave written informed consent for overall project participation with additional consents for endoscopy and treatment. Participants \< 17 years old required written parental consent, with children deemed sufficiently mature providing written assent. Details can be found on the CAN*Help* Working Group website \[[@CR9]\].

*Hp* screening {#Sec7}
--------------

Beginning in January 2008, we offered screening for *Hp* infection using the 13C-urea breath test (UBT), the most accurate non-invasive test for detecting *Hp* infection in children and adults \[[@CR26]\]; most well-designed validation studies estimate both sensitivity and specificity greater than 95% against biopsy-based diagnosis \[[@CR27]\], though it should be noted that biopsy-based diagnosis is not an optimal gold standard because tissue sampling can miss *Hp* in the stomach due to its patchy distribution and diagnostic accuracy also depends on tissue preparation techniques and observer expertise \[[@CR26], [@CR28], [@CR29]\]. The UBT avoids these limitations, but its accuracy depends on optimal breath sample collection \[[@CR30]\]. We used nondispersive isotope-selective infrared spectroscopy to measure the 13C/12C ratio in breath samples collected before and after consumption of 13C-labeled urea \[[@CR31], [@CR32]\]; a positive result reflects presence of urease in the stomach, a highly specific marker for *Hp* infection. We asked participants to avoid acid-suppressing medications for 24 h before the test and to fast except for water for 4 h before the test. We obtained a baseline breath sample, asked participants to swallow 50--75 mg of 13C-labeled urea dissolved in citric acid, and collected a second breath sample 30 min after the urea solution was swallowed \[[@CR17]\].

Upper gastrointestinal endoscopy, histopathology, and microbiological culture {#Sec8}
-----------------------------------------------------------------------------

Using ultra-slim Olympus gastroscopes, gastroenterologists performed unsedated upper gastrointestinal endoscopy for consenting participants, regardless of *Hp* status, in temporary endoscopy clinics organized in community health centers (2008 in Aklavik, 2012 in Old Crow, 2013 in Fort McPherson and at the Inuvik Regional Hospital for Tuktoyaktuk participants) \[[@CR33]\]. The regional planning approach used for the Tuktoyaktuk project created logistic constraints that reduced time periods, relative to the other community projects, for recruiting participants and carrying out project activities; as a result, participation was not sufficient to warrant resources required for an endoscopy team to visit this community. Instead, we offered to pay travel expenses for Tuktoyaktuk residents willing to undergo endoscopy in Inuvik (a 2-h drive). Gastric biopsies collected during endoscopy were transported to the University of Alberta for histopathologic examination (2--3 from antrum, 2--3 from corpus) and tissue culture (1 from antrum, 1 from corpus) \[[@CR14]\]. A single pathologist (SG) evaluated antral and corpus biopsies separately, grading *Hp* density, active and chronic gastritis, gastric atrophy, and other neoplastic lesions using the updated Sydney system \[[@CR34]\]. We differentiate active gastritis, characterized by polymorphonuclear neutrophil infiltration occurring in the context of chronic inflammation, from chronic gastritis, characterized by the presence of mononuclear cells, chiefly lymphocytes, plasma cells and macrophages \[[@CR34]\]. For culture, antral and corpus biopsies were pooled and mechanically homogenized; resulting suspensions were plated on brain heart infusion/yeast extract/5% horse serum agar plates and incubated at 37 °C in microaerophilic conditions. Cultures were checked for growth every 48 h, for up to a month. Colonies consistent with *Hp* growth were sub-plated and expanded for generation of glycerol stocks. *Hp* classification was confirmed by urease, catalase, oxidase and 16S ribosomal RNA PCR testing.

*Hp* infection status {#Sec9}
---------------------

We classified *Hp* infection status using all available results (UBT, histopathologic examination, and/or bacterial culture) for each participant. When results were discordant, we used an algorithm based on the probability that the status was negative or positive (for example, UBT positive + histopathology positive + culture negative was classified as positive; UBT negative + histopathology positive + culture negative was classified as negative). Among 254 participants with classifiable *Hp* status from 3 tests, 216 (85%) were concordant on all 3 tests; among 53 participants with classifiable *Hp* status from just 2 tests, 47 (89%) had concordant status. Of the 3 tests, UBT and histopathology agreed most frequently, for 263 of 272 (97%) participants with results from both, while the results of culture diverged more frequently, agreeing with UBT for 218 of 254 (86%) participants with both of these tests and with histopathology for 252 of 289 (87%) participants with both of these tests. The more frequent discordance of culture is not surprising given the technical challenges inherent in tissue culture of *Hp* in the laboratory \[[@CR30], [@CR35]\]. The high agreement of UBT and histopathology indicates comparable and excellent accuracy of these 2 diagnostic tests. Comparing UBT against histopathology as the gold standard, estimated sensitivity is 96% (95% confidence interval (CI), 94--99%) and estimated specificity is 97% (95% CI, 94--100%). Conversely, comparing histopathology against UBT as the gold standard, estimated sensitivity is 99% (95% CI, 98--100%) and estimated specificity is 91% (95% CI, 85--97%).

Statistical analysis {#Sec10}
--------------------

The cross-sectional design is appropriate for investigations of the burden of disease from *Hp* in a community setting, given that the infection onset generally goes undetected, the infection often persists indefinitely without symptoms, and gastric disease caused by the infection is often asymptomatic. Screening for prevalent cases is, therefore, the starting point for describing the occurrence of *Hp* infection and related disease in a population. To describe the burden of infection in participating communities, we present the estimated prevalence of *Hp* infection and 95% confidence intervals by age, sex, ethnicity and community. To describe the burden of gastric disease related to *Hp* infection and demonstrate relatedness of specific conditions to *Hp* infection, we present the estimated prevalence of endoscopic diagnoses (esophagitis/esophageal erosions, Barrett's esophagus, gastritis, gastric erosions, gastric ulcer, duodenitis, duodenal erosions, duodenal ulcer) and histopathologic diagnoses (active gastritis, chronic gastritis, gastric atrophy, benign MALT hyperplasia or lymphoid aggregates, lymphoepithelial lesions, intestinal metaplasia, dysplasia, carcinoma) and 95% CIs by *Hp* status. In analyses of endoscopy or histopathology results, we excluded the small number of participants who underwent treatment to eliminate *Hp* after the screening UBT and before endoscopy.

Results {#Sec11}
=======

Participation and data availability {#Sec12}
-----------------------------------

The four community projects enrolled 934 participants, representing 38% of the combined populations of these communities (Table [1](#Tab1){ref-type="table"}). The first two community projects had the highest participation, with 64 and 85% of residents of Aklavik and Old Crow, respectively. *Hp* status was available for 878 (94%) of the 934 participants. Table [2](#Tab2){ref-type="table"} shows participation in UBT screening and endoscopy by community, with UBT results available for 90% (841/934) and histopathology results available for 33% (308/934). Due to the logistic challenges, only 5 Tuktoyaktuk residents had eligible histopathology results: each fell in a different age group; 4 were women; 5 were Indigenous (4 were Inuvialuit, the dominant ethnicity in Tuktoyaktuk); and 4 were *Hp*-positive with a distribution of endoscopic and histopathologic outcomes reflective of the larger study population.Table 1Participation in CAN*Help* projects and availability of *Hp* status data, western Arctic Canadian communities, 2007--2013CommunityLaunch YearCensus-estimated^a^ PopulationEnrolled Participants (signed consent)Participants with Data on *H. pylori* Statusn% of Censusn% of ParticipantsAklavik20075943836435292Old Crow20102452088520096Tuktoyaktuk20118541071310295Fort McPherson20127922363022495Total24859343887894^a^From 2006 census for Aklavik \[[@CR18]\]; from 2011 census for other communities \[[@CR19]--[@CR21]\]Table 2Participation in CAN*Help* project diagnostic testing and availability of results, western Arctic Canadian communities, 2008--2013CommunityEnrolled ParticipantsUBTEndoscopyCompletedClassifiable ResultCompletedHistopathology Resultsnn%n%n%n%Aklavik38333487333871965119451Old Crow208199961929259285928Tuktoyaktuk10710497102955555Fort McPherson236228972149150215021Total93486593841903103330833

Table [3](#Tab3){ref-type="table"} shows the distribution of age, sex, community and ethnicity in all 934 participants and in two study population subsets: the 878 with *Hp* status and the 308 with histopathology results. Aside from the exclusion of young children from endoscopy, the age distribution of the two subpopulations approximates that of the total study population. The sex distribution is similar across study population subsets, with women accounting for 54--56% of each. The proportion identifying as Indigenous is 90--92% across study subpopulations. The representation of communities is nearly identical in the total study population and among those with *Hp* status, but among those with histopathology results Aklavik is overrepresented due to a much higher proportion of participants undergoing endoscopy in the first project, and Tuktoyaktuk is underrepresented due to only 13 participants traveling to Inuvik for endoscopy. Just 56 (6%) participants lacked data on *Hp* status; these participants were disproportionately younger and male.Table 3Characteristics of CAN*Help* project participants by data availability, 2007--2013All 934 Participants878 Participants with *Hp* Status308 Participants with Histopathology56 Participants without *Hp* Statusn%^a^n%^a^n%^a^n%^a^Ageχ^2^-*p*-value^b^: 0.006 0--9.75768657001120 9.8--14^c^4554158347 15--24136151241446151222 25--3414215135154515713 35--441211311813411336 45--541701816519752459 55--641331412815571859 65--9610912102123612713 *missing2002*Sexχ^2^-*p*-value^b^: 0.09 Male4304639845137443257 Female5045448055171562443 *missing0000*Communityχ^2^-*p*-value^b^: 0.15 Aklavik3834135240194633155 Old Crow20822200235919814 Tuktoyaktuk10711102125259 Fort McPherson236252242650161221 *missing0000*Ethnicityχ^2^-*p*-value^b^: 0.41 Non-Indigenous8210779228513 Indigenous7759074091271923588  Inuvialuit (Inuit)3053628935121411640  Gwich'in (First Nations)4244940550133451948  Other/mixed^d^46546617600 *missing77611516Hp* H. pylori^a^% of column total minus missing; distributions do not all sum 100% due to rounding^b^For the comparison of the distribution in participant groups with and without *Hp* status^c^The 9.8--14 category includes two participants \< 10: one who was 9 years and 10 months at the time of UBT and 9 years and 11 months at endoscopy, and one who was 9 years and 11 months at the time of UBT with no endoscopy^d^Includes: Métis; mixed Indigenous ethnicities; unspecified Indigenous ethnicity; Indigenous mixed with non-Indigenous ethnicities

*Hp* prevalence {#Sec13}
---------------

Among 878 participants with *Hp* status, 62% were *Hp*-positive (Table [4](#Tab4){ref-type="table"}). The prevalence was 45% (95% CI, 36--55%) in children under 15, 69% (95% CI, 63--74%) in the 15--34-year age group, and 61% (95% CI, 57--66%) in the 35--96-year age group. The prevalence was somewhat higher in men (65%; 95% CI, 60--70%) than women (59%; 95% CI, 55--63%). Across communities, the prevalence ranged from 57% in Tuktoyaktuk to 68% in Old Crow. The largest variation in prevalence was by ethnicity, with non-Indigenous participants having a much lower prevalence (22%; 95% CI, 13--31%) than Indigenous participants (66%; 95% CI, 62--69%).Table 4*Hp* prevalence by demographic characteristics, 878 CAN*Help* project participants with *Hp* status, 2008--2013n*Hp* Prevalencen%95% CITotal8785416258, 65Age 0--9.7565304634, 58 9.8--14^a^41184429, 59 15--24124856960, 77 25--34135936961, 77 35--44118705950, 68 45--541651036255, 70 55--64128786152, 69 65--96102646353, 72Sex Male3982586560, 70 Female4802835955, 63Community Aklavik3522136155, 66 Old Crow2001366862, 74 Tuktoyaktuk102585747, 66 Fort McPherson2241346053, 66Ethnicity Non-Indigenous77172213, 31 Indigenous7404866662, 69  Inuvialuit (Inuit)2891936761, 72  Gwich'in (First Nations)4052606460, 69  Other/mixed^b^46337259, 85 *missing61Hp* H. pylori, *CI* binomial Wald confidence interval^a^The 9.8--14 category includes two participants \< 10: one who was 9 years and 10 months at the time of UBT and 9 years and 11 months at endoscopy, and one who was 9 years and 11 months at the time of UBT with no endoscopy^b^Category includes: Métis; mixed Indigenous ethnicities; unspecified Indigenous ethnicity; mixed Indigenous and non-Indigenous ethnicities

Endoscopic assessment {#Sec14}
---------------------

Table [5](#Tab5){ref-type="table"} shows the prevalence of abnormalities observed during endoscopy by *Hp* status. Of note, 79% of *Hp*-positive participants had gastric mucosa that appeared normal. Visible esophagitis and Barrett's esophagus were more prevalent in *Hp*-negative participants (11 and 7%, respectively) than *Hp*-positive participants (8 and 4%, respectively). Paradoxically, the prevalence of visible gastritis, gastric erosions and gastric ulcers was not markedly different in groups defined by *Hp* status: 12--15% had visible gastritis, 8--11% had gastric erosions, and 3--4% had gastric ulcers. The prevalence of visible duodenal lesions was lower: duodenal lesions were observed in 9% of *Hp*-positive participants and 4% of *Hp*-negative participants. No *Hp*-negative participants had visible duodenal erosions or ulcers and 4% had duodenitis, while 1% of *Hp*-positive participants had duodenal erosions, 1% had duodenal ulcers, and 7% had duodenitis. In all 308 participants with complete endoscopic assessment, the gastric to duodenal ratio was 2 for inflammation, 8 for erosions, and 3 for ulcers. In 271 Indigenous participants, the gastric to duodenal ratio was 2 for inflammation, 6 for erosions, and 8 for ulcers.Table 5Prevalence of endoscopic abnormalities by *Hp* status, 309 CAN*Help* project participants with endoscopy data, 2008--2013*Hp* positive*Hp* negative(*n* = 224)(*n* = 85)n%95% CIn%95% CINormal gastric mucosa^a^1777974, 84657768, 86Normal duodenal mucosa2049187, 95829693, 100Normal gastric and duodenal mucosa^a^1627266, 78627464, 83Esophagitis/esophageal erosions1985, 129115, 19Barrett's esophagus842, 7673, 15Gastric inflammation, erosions, or ulcers^a^462115, 26172012, 29 Gastritis^a^331510, 1910125, 19 Gastric erosions^a^1784, 119115, 19 Gastric ulcer^a^631, 6341, 10Duodenal inflammation, erosions, or ulcers2095, 13341, 10 Duodenitis1674, 11341, 10 Duodenal erosions310, 4000, 4 Duodenal ulcer310, 4000, 4*Hp* H. pylori, *CI* binomial Wald confidence interval (binomial exact CI for numerators \< 10; one-sided binomial exact 97.5% CI for numerators of 0)^a^One *Hp*-negative participant was missing gastric mucosa assessment, so the denominator is 84 for gastric abnormalities among *Hp*-negatives

We examined whether the similar frequencies of endoscopically observed gastric abnormalities in groups defined by *Hp* status were due to previous *Hp* infection eliminated by antimicrobial therapy among *Hp*-negatives or recent use of proton pump inhibitors (PPI) or H2-receptor antagonists (H2RA), which decrease the density of *Hp* organisms, thereby reducing the sensitivity of diagnostic tests. In the 84 *Hp*-negative participants with treatment history data, 30 (36%) had previous treatment; the proportion classified as having normal gastric mucosa was 80% among those treated previously and 77% among those not treated previously (for duodenal mucosa, these proportions were 97 and 96%, respectively). Among 302 participants with medication data, recent PPI/H2RA use was reported by 11% of *Hp*-positives and 27% of *Hp*-negatives. To assess the hypothesis that *Hp*-negatives with abnormal gastric mucosa were false negatives due to medication use, we compared the proportion classified as having normal gastric mucosa by PPI/H2RA use: in 85 *Hp*-negatives, 74% among users and 79% among non-users (for duodenal mucosa, 91 and 98%, respectively); in 218 *Hp*-positives, 68% among users and 80% among non-users (for duodenal mucosa, 96 and 91%, respectively). Thus, this paradox does not appear to be due to previously treated *Hp* infection or medication use among current *Hp*-negatives.

Histopathologic assessment {#Sec15}
--------------------------

Groups defined by *Hp* status had strikingly different frequencies of abnormal histopathology (Table [6](#Tab6){ref-type="table"}). The proportion with normal gastric mucosa was 77% among *Hp*-negative participants evaluated and just 1 of 224 *Hp*-positive participants evaluated. Compared to *Hp*-negative participants, *Hp*-positive participants not only had a much higher prevalence of histologic abnormalities, but they also had a much higher severity gradient, although the frequency of intestinal metaplasia was low in both groups and the difference between groups less striking. Of the 4 *Hp*-negatives with intestinal metaplasia, 2 had a record of previous treatment to eliminate *Hp*.Table 6Severity of gastric pathology by *Hp* status, 308 CAN*Help* project participants with histopathology data, 2008--2013Pathology*Hp* positive (*n* = 224)*Hp* negative (*n* = 84)n%^a^95% CIn%^a^95% CIχ^2^-*p*-value^e^:Normal histopathology^b^ No22399.699, 100192314, 320.000 Yes10.40, 2657768, 86Active gastritis^c^ None731, 6829894, 1000.000 Mild1024639, 52220, 8 Moderate813630, 42000, 4 Severe321410, 19000, 4Chronic gastritis None210, 2738780, 940.000 Mild1784, 1110125, 19 Moderate994438, 51110, 6 Severe1064741, 54000, 4Atrophy None1285751, 648410096, 1000.000 Mild683024, 36000, 4 Moderate23106, 14000, 4 Severe521, 5000, 4Intestinal metaplasia None1858378, 88809591, 1000.002 Mild23106, 14451, 12 Moderate1363, 9000, 4 Severe310, 4000, 4MALT hyperplasia^d^ (*n* = 114; 96 HP+) None331, 9137252, 930.000 Mild343526, 4552810, 53 Moderate454737, 57000, 19 Severe14158, 22000, 19Lymphoid aggregates^d^ (*n* = 194; 128 HP+) Present745849, 66583, 170.000Lymphoepithelial lesions Present731, 6000, 40.101Dysplasia or Carcinoma Present000, 2000, 4n/a*Hp* H. pylori, *CI* binomial Wald confidence interval (binomial exact CI for numerators \< 10; one-sided binomial exact 97.5% CI for numerators of 0)^a^Distributions do not all sum 100% due to rounding^b^Excludes MALT hyperplasia or lymphoid aggregates; includes reactive gastropathy^c^2 *H. pylori*-positive participants lack classification for active gastritis^d^In 2008, presence/absence of lymphoid aggregates was noted without grading MALT hyperplasia; after 2008, MALT hyperplasia was graded instead of noting presence/absence of lymphoid aggregates^e^From score test for trend of odds

The results show good statistical precision for describing the severity distributions of the histopathological outcomes and differentiating these distributions in groups defined by *Hp* status. The study population yields even greater precision for differentiating the presence or absence of these outcomes: active gastritis occurred in 96% (95% CI, 92--98%) of positives and 2% (95% CI, 0--8%) of negatives; chronic gastritis occurred in 99% (95% CI, 98--100%) of positives and 13% (95% CI, 6--20%) of negatives; gastric atrophy occurred in 43% (95% CI, 36--49%) of positives and 0% (95% CI, 0--4%) of negatives; intestinal metaplasia occurred in 17% (95% CI, 12--22%) of positives and 5% (95% CI, 1--12%) of negatives; MALT hyperplasia or lymphoid aggregates occurred in 74% (95% CI, 69--80%) of positives and 12% (95% CI, 5--19%) of negatives; lymphoepithelial lesions occurred in 3% (95% CI, 1--6%) of positives and 0% (95% CI, 0--4%) of negatives. Thus, each of these histopathological outcomes was strongly associated with prevalent *Hp* infection in this population.

Discussion {#Sec16}
==========

This analysis shows a high *Hp*-associated disease burden in four western Canadian Arctic hamlets, with an estimated *Hp* prevalence of 66% among Indigenous residents and 22% among non-Indigenous residents. Among participants examined endoscopically, visible inflammation, erosions and ulcers were more frequent in the stomach relative to the duodenum. Pathological examination revealed a low prevalence of mild abnormalities among *Hp*-negative participants; in contrast, *Hp*-positive participants had a high prevalence of moderate-severe active and chronic gastritis; the prevalence of atrophic gastritis was 43% among *Hp*-positive participants and 0 among *Hp*-negative participants, while the prevalence of intestinal metaplasia was 17% among *Hp*-positive participants and 5% among *Hp*-negative participants.

The pattern of disease observed in this population is consistent with increased risk of stomach cancer \[[@CR36]\]. While no cases of dysplasia or carcinoma were detected, none would be expected due to small numbers. During 2008--2016, 3 of the 726 NT participants in this analysis had gastric cancer diagnosed and reported to the NT Cancer Registry (NT Department of Health and Human Services staff, personal communication, July 2018). While small community sizes preclude meaningful estimates of the frequency of gastric dysplasia or carcinoma, the combined community study population yields good statistical precision for estimating the prevalence and severity distributions of less advanced *Hp*-associated pathological outcomes. The elevated ratio of gastric to duodenal lesions is the inverse of the pattern observed in populations where the risk of stomach cancer is low and *Hp* infection frequently leads to duodenal ulcers \[[@CR36]--[@CR38]\]. The more frequent occurrence of gastric ulcer relative to duodenal ulcer has been observed in other populations at increased risk of stomach cancer \[[@CR37], [@CR38]\]. In addition, chronic gastritis and gastric atrophy are initial stages in Correa's widely accepted model of gastric carcinogenesis \[[@CR39]\]; thus, the high prevalence of these conditions are further indications of increased stomach cancer risk in participating communities.

The estimated prevalence of endoscopically and histopathologically diagnosed gastric disease associated with *Hp* infection in CAN*Help* community project participants is a rare resource given that very few community-based studies have assessed geographically-defined communities for these diagnoses. A recent clinic-based study of 432 Alaska Natives undergoing endoscopic assessment for digestive symptoms estimated similarly high prevalence of stomach pathology in *Hp*-positive participants \[[@CR40]\]; prevalence estimates for Alaska Native patients and Indigenous CAN*Help* project participants, respectively, were 78 and 97% for active gastritis, 98 and 99% for chronic gastritis, and 13 and 17% for intestinal metaplasia \[[@CR40]\]. Estimated prevalence of stomach pathology in *Hp*-negative participants was higher in Alaska Native patients than CAN*Help* project participants, respectively: 18 and 3% for active gastritis; 69 and 14% for chronic gastritis; and 10 and 6% for intestinal metaplasia \[[@CR40]\]. The Alaska Native patients had much higher prevalence of endoscopically detectable gastric disease than the CAN*Help* project participants (for example, 85% of Alaska Native patients had an endoscopic diagnosis of gastritis, in contrast to 14% of CAN*Help* project participants), which is likely to be due, at least in part, to the clinic-based study design that recruited symptomatic patients who would have more severe disease on average than a community-based population \[[@CR40]\]. In addition, the ratio of gastric to duodenal ulcers in the Alaska Native participants was nearly 5 (33:7) \[[@CR40]\].

The pattern of gastric disease observed among *Hp*-positive CAN*Help* community project participants contrasts sharply with the pattern we reported previously for *Hp*-positive patients with gastric biopsies evaluated at the University of Alberta Hospital in Edmonton, Alberta (metro area 2016 census population = 1,321,426) between April 2010 and March 2011 \[[@CR14], [@CR41]\]. In this patient population (*Hp* prevalence = 14% in \~ 3000 patients assessed), of roughly 400 *Hp*-positive patients evaluated, 11% had active gastritis, 40% had mild chronic gastritis, 55% had moderate chronic gastritis, 5% had severe chronic gastritis, and just 2% had gastric atrophy. Thus, compared to an urban southwestern Canadian population of patients of predominantly European ancestry \[[@CR41]\] evaluated for digestive complaints, the community-based study population of residents of predominantly Indigenous western Canadian Arctic hamlets had a prevalence of *Hp* infection over 4 times higher along with a notably more severe pattern of gastric mucosal injury among those infected. This contrast reveals substantial inequity in the disease burden associated with *Hp* infection in western Arctic Canadian hamlets relative to a North American metropolis.

In addition to the small study size for estimating rare outcomes, another limitation of this investigation is the possibility that the participants did not accurately represent the participating communities. Within the constraints of available resources, every effort was made to include all residents of participating communities. If those who did not participate included a greater proportion of community members who were less eager to engage in health care, then we would likely have underestimated the prevalence of *Hp* infection and associated pathology. There was also potential for misclassification of *Hp* status and histopathology outcomes given imperfect diagnostic methods. The accuracy estimates generated by our data for classifying *Hp* status, however, suggest that our *Hp* prevalence estimates are roughly accurate for the study population. Also, the comparison of our histopathology results to those of *Hp-*positive patients evaluated by the University of Alberta Hospital pathology laboratory, where gastric biopsies from our community projects were processed and assessed, enhances the validity of the distinct patterns observed in the Arctic communities.

Conclusions {#Sec17}
===========

We have offered an example of the value of community-driven investigations for generating descriptions of the public health burden from diseases identified by affected communities and their healthcare providers to be of high community impact. This research provides evidence of a high burden of disease from *Hp* infection in Indigenous communities of western Arctic Canada. These results add to a small body of evidence that demonstrates the need for targeted interventions aimed at reducing health risks from *Hp* infection in Indigenous Arctic communities. In keeping with community-university research agreements, all results have been disseminated within participating communities to address voiced concerns and support community efforts to advocate for relevant resources and policies. In addition, our collaborative team has used these disease burden results, along with results from treatment trials and longitudinal follow-up \[[@CR17], [@CR42]\], to create *Hp* clinical guidelines (not yet published) specific to healthcare practitioners serving Arctic communities in Canada.

CAN*Help*

:   Canadian North *Helicobacter pylori*

CI

:   Confidence interval

H2RA

:   H2-receptor antagonist

*Hp*

:   *Helicobacter pylori*

MALT

:   Mucosa-associated lymphoid tissue

NT

:   Northwest Territories

PCR

:   Polymerase chain reaction

PPI

:   Proton pump inhibitor

RNA

:   Ribonucleic acid

UBT

:   13C-urea breath test

YT

:   Yukon
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